Transdermal Patches Market by Product (Matrix, Multi-layer Drug-in-Adhesive, Reservoir), Type (Buprenorphine Transdermal Patch, Clonidine Transdermal Patch, Fentanyl Transdermal Patch), Technology, Application, Distribution Channel, End Users - Global For

Transdermal Patches Market by Product (Matrix, Multi-layer Drug-in-Adhesive, Reservoir), Type (Buprenorphine Transdermal Patch, Clonidine Transdermal Patch, Fentanyl Transdermal Patch), Technology, Application, Distribution Channel, End Users - Global Forecast 2024-2030


The Transdermal Patches Market size was estimated at USD 8.57 billion in 2023 and expected to reach USD 9.89 billion in 2024, at a CAGR 16.40% to reach USD 24.84 billion by 2030.

Transdermal patches offer a novel therapeutic approach to managing chronic conditions by delivering medication directly through the skin into the bloodstream. These patches are used for a range of purposes, including nicotine cessation, hormone replacement therapy, pain management, and the administration of anti-hypertensive, anti-inflammatory, and contraceptive medications. The growing aging population facing difficulty in oral medication administration may benefit from the ease of use of transdermal patches. The prevalence of chronic diseases and the rising preference for non-invasive drug delivery methods are raising the need for transdermal patches. However, high costs and limitations associated with transdermal patches can impede end-user adoption. Moreover, ongoing R&D to develop innovative drug delivery systems and enhance the effectiveness and range of available transdermal drug delivery systems are expected to encourage their use to treat chronic conditions globally.

Regional Insights

The transdermal patches market is developing in the Americas owing to the advanced healthcare infrastructure, high healthcare expenditure, increasing prevalence of chronic diseases, and the presence of key market players actively involved in developing new transdermal technologies. Favorable regulatory policies and a strong focus on research and development activities contribute to the transdermal patch market's growth in the Americas. Europe is another crucial market for transdermal patches owing to the increasing geriatric population with chronic conditions requiring convenient medication delivery options such as transdermal patches. Governments and healthcare organizations across Europe have been advocating for cost-effective treatment methods consistent with an at-home healthcare trend, significantly driving the need for self-administered therapies such as transdermal patches. Health infrastructure and economic developments are improving the accessibility and adoption of transdermal patches by end-users in the Middle East and Africa region. The Asia-Pacific region is emerging as the fastest-growing market for transdermal patches due to increasing healthcare awareness and the growing need for chronic disease management. Improvements in healthcare infrastructure and rising income levels are forecasted to support the growth of the transdermal patches market in the APAC region.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Transdermal Patches Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
  • Increased use of transdermal patches to treat chronic conditions worldwide
  • Rising preference for controlled drug release and non-invasive drug delivery solutions
  • Growing number of government approvals for transdermal patches
Market Restraints
  • High costs associated with transdermal patches
Market Opportunities
  • Ongoing research and development for advanced and highly efficient transdermal drug delivery patches
  • Emerging advances in the formulation and manufacturing of transdermal patches
Market Challenges
  • Limitations associated with transdermal drugs along with product recalls
Market Segmentation Analysis
  • Product: Significant penetration of Multi-layer Drug-in-Adhesive patches
  • Type: Extensive requirement for nicotine transdermal patches
  • Technology: Utilization of chemical enhancers to improve transdermal patch efficacy
  • Application: Expanding use of transdermal patches for hormonal therapy
  • Distribution Channel: Proliferation of transdermal patches on eCommerce platforms
  • End Users: Increasing prescription of transdermal patches in hospitals
Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Transdermal Patches Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Transdermal Patches Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

DifGen Pharmaceuticals Launches A Second Product - Buprenorphine Transdermal System From Its U.S. Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing U.S. Made Transdermal Patches And Sublingual Films

DifGen Pharmaceuticals LLC announced the successful launch of their second complex transdermal product in the U.S. market. This achievement comes within seven months of their first acquisition, marking another significant milestone for the company. With the launch, DifGen aims to establish and expand a local U.S. manufacturing base.

Luye Pharma Ltd Launches New Alzheimer's Treatment In The UK

Luye Pharma Ltd, a subsidiary of Luye Pharma Group, introduced Zeyzelf twice-weekly rivastigmine transdermal patches for the symptomatic treatment of mild to moderately severe Alzheimer's dementia. This launch aligns with Luye Pharma Ltd's commitment to specialize in treatments for CNS diseases, and it exemplifies their vision of offering cost-effective and innovative medications to the UK NHS.

Corsair Pharma Announces USD 23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension

Corsair Pharma secured USD 23 million in Series B financing to advance clinical trials in the field of Pulmonary Arterial Hypertension (PAH). The funding is utilized to further develop their Transdermal Patches for the treatment of PAH and to establish additional clinical trials. This significant investment highlights Corsair Pharma's long-term commitment to provide innovative and effective treatments for patients suffering from PAH.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Transdermal Patches Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Transdermal Patches Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AdhexPharma SAS, ALVOGEN, Amneal Pharmaceuticals, Inc., Bayer AG, BioNxt Solutions Inc., Bliss GVS Pharma Ltd., Boehringer Ingelheim International GmbH, Corium, Inc., Corsair Pharma, Inc., DifGen Pharmaceuticals LLC, Endo International plc, Gedeon Richter Plc, GlaxoSmithKline Plc, Icure Pharmaceutical Inc., Johnson & Johnson Services, Inc., LAVIPHARM GROUP HOLDING S.A., Luye Pharma Group Ltd, Medherant Limited, Nitto Denko Corporation, Novartis AG, Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc., Nutriband Inc, Perrigo Company plc, ProSolus, Inc., Purdue Pharma L.P., Sparsha Pharma International Pvt Ltd, Tapemark by LTS Lohmann Therapie-Systeme AG, Teikoku Seiyaku Co., Ltd., Tesa SE by Beiersdorf AG, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Transdermal Patches Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
  • Matrix
  • Multi-layer Drug-in-Adhesive
  • Reservoir
  • Single-layer Drug-in-Adhesive
  • Type
  • Buprenorphine Transdermal Patch
  • Clonidine Transdermal Patch
  • Fentanyl Transdermal Patch
  • Nicotine Transdermal Patch
  • Oxybutynin Transdermal Patch
  • Technology
  • Chemical Enhancers
  • Electric Current
  • Mechanical Arrays
  • Thermal Ablation
  • Application
  • Hormonal Therapy
  • Overactive Bladder
  • Pain Relief
  • Smoking Reduction & Cessation Aid
  • Distribution Channel
  • Offline
  • Online
  • End Users
  • Clinics
  • Home Care Settings
  • Hospitals
  • Region
  • Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom


Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased use of transdermal patches to treat chronic conditions worldwide
5.1.1.2. Rising preference for controlled drug release and non-invasive drug delivery solutions
5.1.1.3. Growing number of government approvals for transdermal patches
5.1.2. Restraints
5.1.2.1. High costs associated with transdermal patches
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for advanced and highly efficient transdermal drug delivery patches
5.1.3.2. Emerging advances in the formulation and manufacturing of transdermal patches
5.1.4. Challenges
5.1.4.1. Limitations associated with transdermal drugs along with product recalls
5.2. Market Segmentation Analysis
5.2.1. Product: Significant penetration of Multi-layer Drug-in-Adhesive patches
5.2.2. Type: Extensive requirement for nicotine transdermal patches
5.2.3. Technology: Utilization of chemical enhancers to improve transdermal patch efficacy
5.2.4. Application: Expanding use of transdermal patches for hormonal therapy
5.2.5. Distribution Channel: Proliferation of transdermal patches on eCommerce platforms
5.2.6. End Users: Increasing prescription of transdermal patches in hospitals
5.3. Market Trend Analysis
5.3.1. Supportive government approval landscape for transdermal patches in the Americas
5.3.2. Growing prevalence of chronic pain and diabetes propelling the growth of transdermal patches in the APAC region
5.3.3. Improving healthcare infrastructure to increase access of innovative transdermal patches in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Transdermal Patches Market, by Product
6.1. Introduction
6.2. Matrix
6.3. Multi-layer Drug-in-Adhesive
6.4. Reservoir
6.5. Single-layer Drug-in-Adhesive
7. Transdermal Patches Market, by Type
7.1. Introduction
7.2. Buprenorphine Transdermal Patch
7.3. Clonidine Transdermal Patch
7.4. Fentanyl Transdermal Patch
7.5. Nicotine Transdermal Patch
7.6. Oxybutynin Transdermal Patch
8. Transdermal Patches Market, by Technology
8.1. Introduction
8.2. Chemical Enhancers
8.3. Electric Current
8.4. Mechanical Arrays
8.5. Thermal Ablation
9. Transdermal Patches Market, by Application
9.1. Introduction
9.2. Hormonal Therapy
9.3. Overactive Bladder
9.4. Pain Relief
9.5. Smoking Reduction & Cessation Aid
10. Transdermal Patches Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Transdermal Patches Market, by End Users
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Americas Transdermal Patches Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Transdermal Patches Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Transdermal Patches Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. DifGen Pharmaceuticals Launches A Second Product - Buprenorphine Transdermal System From Its U.S. Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing U.S. Made Transdermal Patches And Sublingual Films
15.3.2. Luye Pharma Ltd Launches New Alzheimer's Treatment In The UK
15.3.3. Corsair Pharma Announces USD 23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
15.3.4. Vaxess Raises USD 9 Million to Accelerate mRNA Vaccine Patch Development
15.3.5. Almirall Acquires Rights To Distribute Alzheimer’s Treatment In Spain For An Initial EUR 45 Million
15.3.6. Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY in Multiple Markets Across Asia
15.3.7. Dexmedetomidine Transdermal Patch Fast Tracked for Postop Pain Management
15.3.8. LTS Completes its Entry into Large Molecule Drug Delivery with the Acquisition of the Sorrel Wearable Injection Device Business
15.3.9. BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
15.3.10. Bionxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson’s Disease
15.3.11. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
15.3.12. The Addition of Tesa Labtec GmbH Marks a Cornerstone in AdhexPharma’s Growth Path
16. Competitive Portfolio
16.1. Key Company Profiles
16.2. Key Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings